On the basis of our observations that blocking EGFR signalling in oncogene-driven NSCLC alters the TME towards a proinflammatory status, thus promoting an enhanced immune response, we next examined tumour growth rates by analysing target lesion size to assess tumour response. This evidence concerns the gene EGFR and non-small cell lung carcinoma.